So much has been made about Mylan’s ($MYL) $1.6 billion deal to buy the sterile injectable business of Strides Arcolab that other deals the company has done in India have gotten overlooked. But Mylan has expanded in India with several other small acquisitions on top of the big deal for Agila Specialties.
The drugmaker has just concluded one of those, a 160.50 crore ($26 million) buyout of a new formulation facility in Madhya Pradesh that it picked up from Unichem Laboratories. The drugmakers said in February that they had struck a deal. In the same month Mylan also closed on a $32.5 million deal to buy a nearly new, FDA-approved plant in India from SMS Pharmaceuticals. That plant in Vizag manufactures active pharmaceutical ingredients (APIs) through finished oncology products, including injectable drugs. SMS brought the plant online in 2008.